The Enterprise Value as of September 2024 (TTM) for Protalix BioTherapeutics, Inc. (PLX) is 82.18M

According to Protalix BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 82.18M. This represents a change of -24.79% compared to the average of 109.27M of the last 4 quarters.

Protalix BioTherapeutics, Inc. (PLX) Historical Enterprise Value (quarterly & annually)

How has PLX Enterprise Value performed in the past?

The mean historical Enterprise Value of Protalix BioTherapeutics, Inc. over the last ten years is 377.54M. The current 82.18M Enterprise Value has changed 2.08% with respect to the historical average. Over the past ten years (40 quarters), PLX's Enterprise Value was at its highest in in the September 2014 quarter at 2.26B. The Enterprise Value was at its lowest in in the December 2021 quarter at 32.14M.

Protalix BioTherapeutics, Inc. (PLX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Protalix BioTherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Protalix BioTherapeutics, Inc. (PLX) Average Enterprise Value

How has PLX Enterprise Value performed in the past?

The current Enterprise Value of Protalix BioTherapeutics, Inc. (PLX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Protalix BioTherapeutics, Inc. (PLX) Enterprise Value vs. Peers

How is PLX’s Enterprise Value compared to its peers?

Protalix BioTherapeutics, Inc.’s Enterprise Value is less than Corvus Pharmaceuticals, Inc. (366.18M), less than Aldeyra Therapeutics, Inc. (338.76M), greater than Gamida Cell Ltd. (57.65M), less than Checkpoint Therapeutics, Inc. (100.30M), greater than Cidara Therapeutics, Inc. (-78706946.00), less than Akebia Therapeutics, Inc. (357.42M), greater than X4 Pharmaceuticals, Inc. (50.91M), less than Seres Therapeutics, Inc. (299.11M), greater than eFFECTOR Therapeutics, Inc. (3.86M), greater than PDS Biotechnology Corporation (78.58M), less than aTyr Pharma, Inc. (138.44M), greater than Elevation Oncology, Inc. (8.40M), less than Lexicon Pharmaceuticals, Inc. (0), less than Iovance Biotherapeutics, Inc. (655.68M), less than ImmunoGen, Inc. (2.88B), less than null (8.19B),

Build a custom stock screener for Protalix BioTherapeutics, Inc. (PLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protalix BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protalix BioTherapeutics, Inc. (PLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protalix BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.